Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2012-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/J.1365-2125.2011.04108.XPMID 22442826PMCID PMC3370343
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes.

  2012cited by this paper
• Non-compartmental analysis.

  2012cited by this paper
• Impact of Target‐Mediated Drug Disposition on Linagliptin Pharmacokinetics and DPP‐4 Inhibition in Type 2 Diabetic Patients

  2010cited by this paper
• Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans

  2009cited by this paper
• Disposition of Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Rats and Dogs

  2009cited by this paper
• The Absolute Oral Bioavailability and Population-Based Pharmacokinetic Modelling of a Novel Dipeptidylpeptidase-IV Inhibitor, Vildagliptin, in Healthy Volunteers

  2007cited by this paper
• Dipeptidyl peptidase‐IV inhibitors: a major new class of oral antidiabetic drug

  2007cited by this paper
• Pharmacokinetics and Pharmacodynamics of Vildagliptin in Patients with Type 2 Diabetes Mellitus

  2007cited by this paper
• A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples

  2007cited by this paper
• Biology of incretins: GLP-1 and GIP.

  2007cited by this paper
• The Role of Vildagliptin in the Management of Type 2 Diabetes Mellitus

  2007cited by this paper
• Target-mediated drug disposition and dynamics.

  2006cited by this paper
• Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile).

  2005cited by this paper
• 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.

  2003cited by this paper
• Ways to Fit a PK Model with Some Data Below the Quantification Limit

  2001cited by this paper
• General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition

  2001cited by this paper
• Nonlinearity detection: Advantages of nonlinear mixed-effects modeling

  2000cited by this paper
• NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV.

  1999cited by this paper
• Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides.

  1999cited by this paper
• Pharmacologic target‐mediated drug disposition

  1994cited by this paper

• Preclinical Modeling and Simulation to Explore the Tissue/Plasma Exposure and Pharmacodynamic Effect of Vildagliptin in Diabetes Treatment

  2026cites this paper
• Optimizing Zanubrutinib Dosing in Patients: A PBPK‐BO Model Approach to Drug–Drug Interactions and Patients with Hepatic Impairment

  2025cites this paper
• A physiologically-based quantitative systems pharmacology model for mechanistic understanding of the response to alogliptin and its application in patients with renal impairment

  2025cites this paper
• A Comprehensive Physiologically Based Pharmacokinetic Model for Predicting Vildagliptin Pharmacokinetics: Insights into Dosing in Renal Impairment

  2024cites this paper
• Individual Components of Polymyxin B Modeled via Population Pharmacokinetics to Design Humanized Dosage Regimens for a Bloodstream and Lung Infection Model in Immune-Competent Mice

  2023cites this paper
• A model‐informed approach to accelerate the clinical development of cofrogliptin (HSK7653), a novel ultralong‐acting dipeptidyl peptidase‐4 inhibitor

  2023cites this paper
• A systematic review on the clinical pharmacokinetics of vildagliptin in healthy and disease populations

  2023influential citation
• Prediction of pharmacokinetics and pharmacodynamics of trelagliptin and omarigliptin in healthy humans and in patients with renal impairment using physiologically based pharmacokinetic combined DPP-4 occupancy modeling.

  2022cites this paper
• Design, Synthesis and Biological Evaluation of Neogliptin, a Novel 2-Azabicyclo[2.2.1]heptane-Based Inhibitor of Dipeptidyl Peptidase-4 (DPP-4)

  2022cites this paper
• First-in-human safety, tolerability, and pharmacokinetics of SY-007, a prolonged action neuroprotective drug for ischemic stroke, in healthy Chinese subjects.

  2021cites this paper
• Impact of target‐mediated drug disposition on hetrombopag pharmacokinetics and pharmacodynamics in Chinese healthy subjects and patients with chronic idiopathic thrombocytopenic purpura

  2021cites this paper
• Seeking Nonspecific Binding: Assessing the Reliability of Tissue Dilutions for Calculating Fraction Unbound

  2020cites this paper
• Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease

  2020cites this paper
• Effect of Food on the Pharmacokinetic and Pharmacodynamic Profiles of Hetrombopag in Healthy Volunteers.

  2020cites this paper
• Concept of Pharmacologic Target‐Mediated Drug Disposition in Large‐Molecule and Small‐Molecule Compounds

  2019cites this paper
• Single-dose escalation study of yogliptin in healthy Chinese volunteers.

  2019cites this paper
• Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule–Related Therapeutic Modalities

  2019cites this paper
• Multi-scale modeling of drug binding kinetics to predict drug efficacy

  2019cites this paper
• Utilization of data below the analytical limit of quantitation in pharmacokinetic analysis and modeling: promoting interdisciplinary debate.

  2018cites this paper
• Importance of target-mediated drug disposition for small molecules.

  2018cites this paper
• Mechanistic modelling of drug target binding kinetics as determinant of the time course of drug action in vivo

  2017cites this paper
• Small‐Molecule Compounds Exhibiting Target‐Mediated Drug Disposition (TMDD): A Minireview

  2017cites this paper
• Mechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients

  2016cites this paper
• Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods.

  2016cites this paper
• A Comprehensive Review of Novel Drug–Disease Models in Diabetes Drug Development

  2016cites this paper
• Pharmacokinetics applications of traditional Chinese medicines

  2016cites this paper
• New Developments in the Use of Biomarkers in Translational Medicine

  2016cites this paper
• Target-mediated pharmacokinetic/pharmacodynamic model based meta-analysis and dosing regimen optimization of a long-acting release formulation of exenatide in patients with type 2 diabetes mellitus.

  2015cites this paper
• Population Pharmacokinetic/Pharmacodynamic Modelling of Dipeptidyl Peptidase IV Inhibitors

  2015cites this paper
• A Tutorial on Target-Mediated Drug Disposition (TMDD) Models

  2015cites this paper
• Pharmaceutical Equivalent study of Vildagliptin Formulation

  2015cites this paper
• Time of effect duration and administration interval for sitagliptin in patients with kidney failure

  2014cites this paper
• Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?

  2014cites this paper
• Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles

  2012cites this paper
• Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes.

  2012cites this paper
• Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus

  2010cites this paper